Close Menu

NEW YORK (GenomeWeb) – Biocartis announced today that it has partnered with AstraZeneca on a European study designed to obtain faster lung cancer molecular diagnostics results.

As part of the agreement, the firms will begin a prospective lung cancer study using Biocartis' Idylla EGFR mutation test in European countries including Belgium, France, Germany, and Italy.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.